ArticleFrontiers in nutrition2026
Berberine improves lipid levels, vascular function, and gut microbial-dependent metabolites in stable coronary artery disease patients.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine (BBR) has been demonstrated to exert cardiovascular protective effects by regulating lipids and ameliorating inflammation. Recent studies reported the interaction between BBR and gut microbiota in various metabolic diseases due to its low bioavailability. However, few studies examine the effect of BBR on the gut microbiota in coronary artery disease (CAD) individuals. We hence conducted a parallel-controlled, regularly visited clinical trial with 23 stable CAD patients who recently underwent percutaneous coronary intervention and completed a 12-week BBR ± standard therapy treatment. The BBR intervention was associated with a directional improvement in endothelial function, enhanced levels of low-density lipoprotein cholesterol (LDL-C), and a reduction in circulating inflammatory mediators (IL-1α, IL-17, MCP-1, MIP-1β, and VEGF). Using metagenomics and metabolomic studies, we identified that bacterial signatures varied significantly with gradually increasing doses of BBR. These results showed that a specific group of short-chain fatty acid (SCFA)-producing bacteria, mainly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.